Skip to main content

Table 1 Pharmacotherapy

From: Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience

MEDICATION DOSAGE ON- OR
OFF-LABEL?
NUMBER OF SUBJECTS (% OF TOTAL) PARTIAL USE (NUMBER OF SUBJECTS)
LIRAGLUTIDE 1.8 mg daily Off-label (during the study period)
On-label (2016 Nov)
39 (90.7%) 1 < 6 months
1 6–11 months
SGLT2 INHIBITORS Canagliflozin 300 mg daily
Dapagliflozin 10 mg daily
Off-label 37 (86.0%) 5 < 6 months
ORLISTAT 120 mg B.I.D. On-label 34 (79.1%) 4 < 6 months
3 6–11 months
METFORMIN 2000 mg daily Off-label 28 (65.1%) 2 < 6 months
BUPROPION +
NALTREXONE
300 mg + 32 mg daily On-label (USA)
Off-label (Brazil)
25 (58.1%) 2 < 6 months
10 6–11 months
SIBUTRAMINE 10-15 mg daily On-label (Brazil)
Prohibited (USA)
23 (53.5%) 3 < 6 months
TOPIRAMATE 100 mg daily On-label (USA)
(when combined with phentermine)
Off-label (Brazil)
13 (30.2%) 4 < 6 months
TESTOSTERONE 1000 mg I.M. every 3 months On-label
(when hypogonadism is present)
12 (27.9%) -
FLUOXETINE 20-60 mg daily Off-label 11 (25.6%) 1 < 6 months
SERTRALINE 50-200 mg daily Off-label 10 (23.3%) 1 < 6 months